<info type="GeneOrGeneProduct">PKC-alpha</info> attenuates <info type="ChemicalEntity">lithium</info>-induced <info type="DiseaseOrPhenotypicFeature">nephrogenic diabetes insipidus</info>.

<info type="ChemicalEntity">Lithium</info>, an effective antipsychotic, induces <info type="DiseaseOrPhenotypicFeature">nephrogenic diabetes insipidus</info> (<info type="DiseaseOrPhenotypicFeature">NDI</info>) in  40% of patients. The decreased capacity to concentrate urine is likely due to <info type="ChemicalEntity">lithium</info> acutely disrupting the <info type="GeneOrGeneProduct">cAMP</info> pathway and chronically reducing <info type="GeneOrGeneProduct">urea transporter</info> (<info type="GeneOrGeneProduct">UT-A1</info>) and <info type="GeneOrGeneProduct">water channel</info> (<info type="GeneOrGeneProduct">AQP2</info>) expression in the inner medulla. Targeting an alternative signaling pathway, such as <info type="GeneOrGeneProduct">PKC</info>-mediated signaling, may be an effective method of treating <info type="ChemicalEntity">lithium</info>-induced <info type="DiseaseOrPhenotypicFeature">polyuria</info>. <info type="GeneOrGeneProduct">PKC-alpha null mice</info> (<info type="GeneOrGeneProduct">PKCa KO</info>) and strain-matched <info type="GeneOrGeneProduct">wild type</info> (<info type="GeneOrGeneProduct">WT</info>) controls were treated with <info type="ChemicalEntity">lithium</info> for 0, 3 or 5 days. <info type="GeneOrGeneProduct">WT</info> mice had increased urine output and lowered urine osmolality after 3 and 5 days of treatment whereas <info type="GeneOrGeneProduct">PKCa KO</info> mice had no change in urine output or concentration. Western blot analysis revealed that <info type="GeneOrGeneProduct">AQP2</info> expression in medullary tissues was lowered after 3 and 5 days in <info type="GeneOrGeneProduct">WT</info> mice; however, <info type="GeneOrGeneProduct">AQP2</info> was unchanged in <info type="GeneOrGeneProduct">PKCa KO</info>. Similar results were observed with <info type="GeneOrGeneProduct">UT-A1</info> expression. Animals were also treated with <info type="ChemicalEntity">lithium</info> for 6 weeks. <info type="ChemicalEntity">Lithium</info>-treated <info type="GeneOrGeneProduct">WT</info> mice had 19-fold increased urine output whereas treated <info type="GeneOrGeneProduct">PKCa KO</info> animals had a 4-fold increase in output. <info type="GeneOrGeneProduct">AQP2</info> and <info type="GeneOrGeneProduct">UT-A1</info> expression was lowered in 6 week <info type="ChemicalEntity">lithium</info>-treated <info type="GeneOrGeneProduct">WT</info> animals whereas in treated <info type="GeneOrGeneProduct">PKCa KO</info> mice, <info type="GeneOrGeneProduct">AQP2</info> was only reduced by 2-fold and <info type="GeneOrGeneProduct">UT-A1</info> expression was unaffected. Urinary sodium, potassium and calcium were elevated in <info type="ChemicalEntity">lithium</info>-fed <info type="GeneOrGeneProduct">WT</info> but not in <info type="ChemicalEntity">lithium</info>-fed <info type="GeneOrGeneProduct">PKCa KO</info> mice. Our data show that ablation of <info type="GeneOrGeneProduct">PKCa</info> preserves <info type="GeneOrGeneProduct">AQP2</info> and <info type="GeneOrGeneProduct">UT-A1</info> protein expression and localization in <info type="ChemicalEntity">lithium</info>-induced <info type="DiseaseOrPhenotypicFeature">NDI</info>, and prevents the development of the severe <info type="DiseaseOrPhenotypicFeature">polyuria</info> associated with <info type="ChemicalEntity">lithium</info> therapy.